|

Decoding the Inflammasome Influence on Treatment Response in Acute Myeloid Leukemia

RECRUITINGSponsored by Ciceri Fabio
Actively Recruiting
SponsorCiceri Fabio
Started2025-02-22
Est. completion2026-01-31
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06535113

Summary

The study is designed as a collection of biological samples of newly diagnosed acute myeloid leukemia (AML) patients treated in the clinical units involved. Samples of peripheral blood (PB) and bone marrow (BM) will be analyzed to determine the Inflammasome profile before and after a first-line chemotherapy treatment.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Any gender,
* Adults (\>18 years old),
* New suspect diagnosis of acute myeloid leukemia (ELN2022 Criteria)
* Capable of comprehend the study and the consent form,
* Willing to sign the informed consent for the study.

For the retrospective population we will select:

biological samples (BM Biopsies, BM Aspirates and PB) already banked upon research purpose informed consent and collected from the 01/06/2006 up to 01/06/2024 from adults patients with diagnosis of acute myeloid leukemia according to ELN2017 Criteria.

Exclusion Criteria:

* Pediatric patients (\<18 years old),
* Patients unable or unwilling to sign the informed consent.

Conditions2

Acute Myeloid LeukemiaCancer

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.